Boston Scientific Corporation $BSX Shares Sold by Massachusetts Financial Services Co. MA

Key Points

• Massachusetts Financial Services trimmed its Boston Scientific stake by 12.4% in Q4, selling 1,281,765 shares and retaining 9,085,528 shares valued at about $866.3M, while institutional investors hold roughly 89.1% of BSX.
• Boston Scientific beat Q4 EPS estimates ($0.80 vs. $0.78) with revenue of $5.29B (up 15.9% YoY) and set FY2026 guidance of 3.430–3.490 EPS (Q1 guidance 0.780–0.800), versus a current-year analyst consensus of 2.85 EPS.
• Near-term outlook is mixed: the FDA cleared the Asurys Fluid Management System (a growth-positive development), but a securities class action and analyst target cuts (including Citigroup) create legal and sentiment risks.

Massachusetts Financial Services Co. MA lessened its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,085,528 shares of the medical equipment provider's stock after selling 1,281,765 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.61% of Boston Scientific worth $866,305,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Vanguard Group Inc. grew its position in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock valued at $1,656,131,000 after acquiring an additional 111,826 shares during the last quarter. Northern Trust Corp lifted its stake in Boston Scientific by 0.9% during the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider's stock worth $1,406,129,000 after purchasing an additional 128,188 shares during the last quarter. Amundi lifted its stake in Boston Scientific by 17.5% during the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider's stock worth $1,158,619,000 after purchasing an additional 1,781,830 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Boston Scientific by 4.6% in the third quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider's stock worth $1,020,934,000 after purchasing an additional 463,889 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

BSX stock opened at $61.72 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock has a market capitalization of $91.72 billion, a price-to-earnings ratio of 31.81, a PEG ratio of 0.95 and a beta of 0.78. Boston Scientific Corporation has a 1 year low of $60.59 and a 1 year high of $109.50. The stock's fifty day moving average is $71.47 and its two-hundred day moving average is $88.14.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm's quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA cleared Boston Scientific’s Asurys Fluid Management System (510(k)), a perioperative fluid-management product that expands the company’s procedural portfolio and supports recurring consumables revenue and long-term growth narrative. This type of clearance can help justify premium growth multiples if adoption follows. Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System
• Neutral Sentiment: Street forecasts and FY2026 earnings expectations are being updated across outlets; investors should watch consensus revisions which can drive near-term volatility even if underlying fundamentals stay intact. Equities Analysts Offer Predictions for BSX FY2026 Earnings
• Neutral Sentiment: Sector moves and startup funding (e.g., E2’s $80M raise for thrombectomy tech) highlight ongoing competition and innovation in device segments where Boston Scientific competes; these developments are worth monitoring for market-share and M&A implications. E2 raises $80M to market thrombectomy platform
• Negative Sentiment: Multiple law firms have issued shareholder alerts and a securities class action has been filed, with a May 4, 2026 deadline for lead plaintiff motions. Consolidation of claims or a lead plaintiff could increase litigation costs, create disclosure risk, and pressure sentiment while the case proceeds. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: At least one major broker (Citigroup) has lowered expectations for BSX, which can prompt further analyst downgrades and price pressure if others follow. Monitor analyst notes for revised revenue/margin forecasts. Citigroup Has Lowered Expectations for Boston Scientific NYSE: BSX Stock Price

Analyst Upgrades and Downgrades

BSX has been the subject of several recent research reports. Argus upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. Raymond James Financial reaffirmed an "outperform" rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Citigroup dropped their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a "buy" rating on the stock in a research note on Tuesday. Royal Bank Of Canada reissued an "outperform" rating and issued a $115.00 target price on shares of Boston Scientific in a report on Monday, March 30th. Finally, Mizuho cut their target price on shares of Boston Scientific from $140.00 to $115.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $104.05.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.